Author:
Ai Xinghao,Mao Feng,Shen Shengping,Shentu Yang,Wang Jiejun,Lu Shun
Funder
Major Key Project of Shanghai Chest Hospital Science & Technology foundation
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference34 articles.
1. Zheng R, Zeng H, Zhang S, Fan Y, Qiao Y, Zhou Q, et al. Lung cancer incidence and mortality in China, 2010. Thoracic Cancer. 2016;7(1):94–99.
2. Hermann TW, Yen W-C, Tooker P, Fan B, Roegner K, Negro-Vilar A, et al. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer. 2005;50:9–18.
3. Rizvi NA, Marshall JL, Dahut W, Ness E, Truglia JA, Loewen G, et al. A phase I study of LGD1069 in adults with advanced cancer. Clin Cancer Res. 1999;5:1658–64.
4. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol. 1997;15:790–5.
5. Luo W, Schork NJ, Marschke KB, Ng S-C, Hermann TW, Zhang J, et al. Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer. Anticancer Res. 2011;31:2303–11.
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献